GENBGenerate Biomedicines, Inc.

$16.15

The financials

Generate Biomedicines, Inc. by the numbers

Generate Biomedicines, Inc. (GENB) reported revenue of $6.3M in Q2 2026 (quarter ended June 30, 2026), down 28% from the same quarter a year earlier. That came with net loss of $67M.

Generate Biomedicines, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Revenue$6.3M$8.8M−28%
Operating income−$72M−$48Mn/a
Net income−$67M−$42Mn/a
Diluted EPS−$0.52−$1.62n/a